EP08.02-052 Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients with BRAF V600E- Mutation Positive Metastatic NSCLC

Y. Fan,Z. Jianying,Z. Yuanyuan,Y. Yan,Y. Nong,L. Juan,W. Jialei,Z. Jun,W. Zhehai,C. Jun,T. Zhu,H. Li,Z. Li
DOI: https://doi.org/10.1016/j.jtho.2022.07.734
IF: 20.121
2022-01-01
Journal of Thoracic Oncology
Abstract:The prevalence of BRAF V600 mutation in Chinese patients with non-small cell lung cancer (NSCLC) is 1.7%-1.8%; however, no BRAF targeted therapy is currently approved in China. The combination of dabrafenib plus trametinib is approved in the United States, the European Union, Japan and other countries for the treatment of BRAF- mutated NSCLC. The study evaluated the efficacy and safety of dabrafenib plus trametinib in Chinese patients with BRAF V600E- mutated metastatic NSCLC.
What problem does this paper attempt to address?